Neil Versel

As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.

Pictured: Hands exchanging money for medical science objects/Taylor Tieden for BioSpace

Pictured: U.S. and Chinese flags in concrete, broken in the middle/iStock, ffikretow

This is the first round in a series of cuts that will cost 75 people their jobs this year, according to a WARN notice. Employees in other states are affected as well.

Pictured: Illustration depicting large layoffs/iStock, Andrii Yalanskyi

Pictured: Judicial gavel and scales of justice/Courtesy iStock A federal judge in New Jersey on Monday ruled that the drug price negotiations

The Celularity CEO and founder tells BioSpace he believes that placenta-derived cells are the future of stem cell therapies to fight autoimmune disease, cancer, even aging.

Pictured: Collage of the U.S. Capitol, pills, money and justice statue/Taylor Tieden for BioSpace

Since the 2022 launch of ChatGPT, biopharma has poured money into this new form of artificial intelligence, but companies remain cautious with unproven technology.

Pictured: AI robot holding biopharma-related items in hands/Taylor Tieden for BioSpace